Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Executive Summary
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.
You may also be interested in...
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.
Antibiotic Development Incentives Could GAIN Support From Pipeline Survey
A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.